These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4005562)

  • 21. Effects of dopamine agonists on excitatory inputs to nucleus accumbens neurons from the amygdala: modulatory actions of cholecystokinin.
    Liang RZ; Wu M; Yim CC; Mogenson GJ
    Brain Res; 1991 Jul; 554(1-2):85-94. PubMed ID: 1681991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opposite effects of sulfated cholecystokinin on DA-sensitive adenylate cyclase in two areas of the rat nucleus accumbens.
    Studler JM; Reibaud M; Herve D; Blanc G; Glowinski J; Tassin JP
    Eur J Pharmacol; 1986 Jul; 126(1-2):125-8. PubMed ID: 3758156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of dopaminergic neurotransmission in the hypermotility response produced by the administration of N-methyl-D-aspartic acid into the nucleus accumbens.
    Boldry RC; Uretsky NJ
    Neuropharmacology; 1988 Jun; 27(6):569-77. PubMed ID: 2901677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro.
    Voigt M; Wang RY; Westfall TC
    J Pharmacol Exp Ther; 1986 Apr; 237(1):147-53. PubMed ID: 3958963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholecystokinin potentiation of dopamine-mediated behaviors in the nucleus accumbens.
    Crawley JN
    Ann N Y Acad Sci; 1985; 448():283-92. PubMed ID: 3861122
    [No Abstract]   [Full Text] [Related]  

  • 26. Cholecystokinin octapeptide in vitro and ex vivo strongly modulates striatal dopamine D2 receptors in rat forebrain sections.
    Li XM; Hedlund PB; Fuxe K
    Eur J Neurosci; 1995 May; 7(5):962-71. PubMed ID: 7613631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat.
    Hamilton M; Sheehan MJ; De Belleroche J; Herberg LJ
    Neurosci Lett; 1984 Jan; 44(1):77-82. PubMed ID: 6717857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats.
    Koshikawa N; Kikuchi de Beltrán K; Saigusa T; Kobayashi M; Stephenson JD
    Eur J Pharmacol; 1991 Dec; 209(1-2):75-80. PubMed ID: 1814762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presynaptic modulation of dopamine-induced locomotor activity of oxotremorine in nucleus accumbens of the rat.
    de Belleroche JS; Winn P; Murzi E; Williams SF; Herberg LJ
    J Neural Transm; 1982; 54(3-4):134-43. PubMed ID: 6813423
    [No Abstract]   [Full Text] [Related]  

  • 30. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor.
    Pu SF; Zhuang HX; Han JS
    Brain Res; 1994 Sep; 657(1-2):159-64. PubMed ID: 7820614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro.
    Brodie MS; Dunwiddie TV
    Brain Res; 1987 Nov; 425(1):106-13. PubMed ID: 3427413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.
    Daugé V; Steimes P; Derrien M; Beau N; Roques BP; Féger J
    Pharmacol Biochem Behav; 1989 Sep; 34(1):157-63. PubMed ID: 2626446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levels of CCK immunoreactivity and dopamine in the nucleus accumbens after 6-hydroxydopamine lesions of the ventral tegmental area and the nucleus accumbens.
    Igarashi Y; Wiegant VM; Van Ree JM
    Neuropeptides; 1989; 14(2):71-6. PubMed ID: 2812290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of CCK-8 in the nucleus accumbens.
    DeFrance JF; Sikes RW; Chronister RB
    Peptides; 1984; 5(1):1-6. PubMed ID: 6324144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens.
    Crawley JN
    Brain Res; 1988 Nov; 473(2):398-400. PubMed ID: 3233498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overflow of dopamine and cholecystokinin in rat nucleus accumbens in response to acute drug administration.
    Hamilton ME; Redondo JL; Freeman AS
    Synapse; 2000 Dec; 38(3):238-42. PubMed ID: 11020226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of cholecystokinin release from posterior nucleus accumbens by D-2 dopamine receptor.
    Martin JR; Beinfeld MC; Wang RY
    Brain Res; 1986 Nov; 397(2):253-8. PubMed ID: 2948613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.
    Marshall FH; Barnes S; Pinnock RD; Hughes J
    Br J Pharmacol; 1990 Apr; 99(4):845-8. PubMed ID: 2361176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrophysiological effects of cholecystokinin: central dopaminergic systems.
    Wang RY; White FJ
    Prog Clin Biol Res; 1985; 192():95-103. PubMed ID: 4080721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.